Innate Pharma announces its turnover for the first nine months of 2011 and updates on its cash position

Turnover of 3.1 million euros
Cash position as at September 30, 2011 of 49.3 million euros

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces a turnover of 3.1 million euros for the first nine months of 2011, compared with 0.2 million euros for the same period in 2010.